Analysis of ‘Revolving Door' Patients in Opioid Dependent Patients: the Impact of Treatment Discontinuation on Relapse Rates and Health Care Costs in us Public Health Insurance Claims

Buprenorphine/naloxone (BUP/NAL) combination is a well known treatment for opioid dependence. As a chronic relapsing disorder, some patients alternate between periods of on treatment and off treatment. The aim of this study was to compare health care resource utilization and costs between these patients and patients treated continuously. (Source: Value in Health)

Diversion of Methadone and Buprenorphine by Patients in Opioid Substitution Treatment in Sweden: Prevalence Estimates and Risk Factors

Dependence on heroin or other opiates is a condition which is difficult to treat. Research has been unable to point to any clear evidence of lasting effects of medication-free treatment. The dominant treatment method is opioid substitution treatment (OST) with methadone or buprenorphine, the latter often combined with naloxone. Metastudies show that OST is effective in light of factors such as mortality, morbidity, illicit drug use, and criminality.(Mattick, Kimber, Breen, & Davoli, 2008; Mattick, Breen, Kimber, & Davoli, 2009; Amato, Minozzi, Davoli, & Vecchi, 2011)OST also carries risks. (Source: International Journal of Drug Policy)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.

Diversion of Methadone and Buprenorphine by Patients in Opioid Substitution Treatment in Sweden: Prevalence Estimates and Risk Factors

Dependence on heroin or other opiates is a condition which is difficult to treat. Research has been unable to point to any clear evidence of lasting effects of medication-free treatment. The dominant treatment method is opioid substitution treatment (OST) with methadone or buprenorphine, the latter often combined with naloxone. Metastudies show that OST is effective in light of factors such as mortality, morbidity, illicit drug use, and criminality.(Mattick, Kimber, Breen, & Davoli, 2008; Mattick, Breen, Kimber, & Davoli, 2009; Amato, Minozzi, Davoli, & Vecchi, 2011)OST also carries risks. (Source: International Journal of Drug Policy)

MedWorm Sponsor Message: MedWorm Search is coming back soon. Watch this space…

Opioid Addicted Buprenorphine Injectors: Drug Use During And After 12-weeks of Buprenorphine-Naloxone or Methadone in the Republic of Georgia

Assess the prevalence of non-opioid drug use among opioid-addicted, buprenorphine injecting individuals in Georgia, during and after a 12-week course of buprenorphine-naloxone (Suboxone®) or methadone. (Source: Journal of Substance Abuse Treatment)

MedWorm Sponsor Message: MedWorm Search is coming back soon. Watch this space…